Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid Development Strategies In Pediatrics To Get FDA Advisory Panel Help

Executive Summary

While FDA has long required pediatric analgesic studies, very few sponsors have managed to complete them, mainly due to enrollment challenges; advisory committees will offer recommendations on other designs that may bring a more successful result.

You may also be interested in...

Pediatric Opioid Development Faces Grim Outlook After Advisory Cmte.

Panelists appeared to have more questions than answers as the common cliché of 'more research is needed' dominated the two-day meeting.

Opioid Studies In Children Still Facing Design Challenges

FDA cites Purdue and Mallinckrodt over required assessments for Dilaudid and Xartemis XR, respectively; Merck also draws letter for failing to timely submit a PREA study labeling change for the antibiotic Cubicin.

Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data

After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts